News | November 05, 2007

PAT Technology Diagnoses Early Cardiovascular Disease

November 4, 2007 - Itamar Medical announced that four presentations at AHA, including one from the Framingham Heart Study, link PAT signal with several cardiovascular conditions and risk factors as the technology gains broader acceptance.

The Endo-PAT, developed by Itamar Medical, is a FDA approved noninvasive device that detects a pathology called endothelial dysfunction. The condition refers to an impairment of the endothelial layer and is emerging as a key precursor for the development of atherosclerosis.

The noninvasive Endo-PAT device, based on PAT technology, measures subtle but significant vaso-motion changes through a small thimble-like probe placed over a person's index finger. Tests administered with the Endo-PAT provide clinicians and researchers an effective tool for the detection of endothelial dysfunction. Early detection has the potential to reduce the medical and cost burden of cardiovascular disease. Valuable diagnostic information can be obtained from the Endo-PAT at a fraction of the cost of other established approaches which can only be administered by a skilled technician and even then are too operator dependent.

In addition to the data from the Framingham Heart Study, that showed in a large population base study an association between the Endo-PAT results and several risk factors, three other oral presentations from Britain and Sweden showed the relevancy of endothelial function assessment with the Endo-PAT in other conditions in children and adults.

Based on the new studies that support for Endo- PAT as a significant tool in the prevention and management of cardiovascular disease, combined with successful trials of the Endo-PAT at the Mayo Clinic, Harvard University and other academic medical centers, Itamar Medical is now ready to make Endo-PAT Technology available to clinicians beyond the research environment and into the general medical community.

For more information: www.itamar-medical.com

Related Content

Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Overlay Init